CRSP (STOCKS)
CRISPR Therapeutics AG
$54.750000
+3.530000 (+6.89%)
Prev close: $51.220000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Samarth Kulkarni
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5,260.00M
- Employees
- 393
- P/E (TTM)
- -7.86
- P/B (TTM)
- 2.56
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
13
Buy
12
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.37 | $-1.17 | -0.1955 | -16.65% |
|
Sep 2025 (Q3)
|
$-1.17 | $-1.28 | +0.1097 | +8.57% |
|
Jun 2025 (Q2)
|
$-1.29 | $-1.45 | +0.1594 | +11.00% |
|
Mar 2025 (Q1)
|
$-1.58 | $-1.28 | -0.3044 | -23.86% |
Financial Statements
| Revenues | $3.51M |
| Benefits Costs and Expenses | $581.48M |
| Costs And Expenses | $581.48M |
| Nonoperating Income/Loss | $86.61M |
| Operating Expenses | $668.08M |
| Research and Development | $284.81M |
| Other Operating Expenses | $383.28M |
| Operating Income/Loss | -$664.57M |
| Income/Loss From Continuing Operations After Tax | -$581.60M |
| Income/Loss From Continuing Operations Before Tax | -$577.97M |
| Income Tax Expense/Benefit | $3.63M |
| Income Tax Expense/Benefit, Current | $2.72M |
| Income Tax Expense/Benefit, Deferred | $915.00K |
| Net Income/Loss | -$581.60M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$581.60M |
| Net Income/Loss Available To Common Stockholders, Basic | -$581.60M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$6.47 |
| Diluted Earnings Per Share | -$6.47 |
| Basic Average Shares | 89,925,109 |
| Diluted Average Shares | 89,925,109 |
| Assets | $2.27B |
| Current Assets | $1.99B |
| Noncurrent Assets | $279.57M |
| Fixed Assets | $115.85M |
| Other Non-current Assets | $163.72M |
| Liabilities | $343.43M |
| Current Liabilities | $149.12M |
| Accounts Payable | $11.14M |
| Wages | $12.97M |
| Other Current Liabilities | $125.02M |
| Noncurrent Liabilities | $194.31M |
| Equity | $1.92B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.92B |
| Liabilities And Equity | $2.27B |
| Net Cash Flow From Operating Activities | -$345.01M |
| Net Cash Flow From Operating Activities, Continuing | -$345.01M |
| Net Cash Flow From Investing Activities | -$31.81M |
| Net Cash Flow From Investing Activities, Continuing | -$31.81M |
| Net Cash Flow From Financing Activities | $426.03M |
| Net Cash Flow From Financing Activities, Continuing | $426.03M |
| Net Cash Flow | $49.21M |
| Net Cash Flow, Continuing | $49.21M |
| Comprehensive Income/Loss | -$578.62M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$578.62M |
| Other Comprehensive Income/Loss | $2.98M |
| Other Comprehensive Income/Loss Attributable To Parent | -$2.98M |